Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arbutus Biopharma Corp
(NQ:
ABUS
)
3.870
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Arbutus Biopharma Corp
< Previous
1
2
Next >
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
July 12, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Appoints Two New Executives
July 10, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
June 21, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
June 21, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
June 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present at Jefferies Healthcare Conference
May 31, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present at JMP Securities Life Sciences Conference
May 09, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
May 04, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
April 27, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
April 25, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
April 20, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
April 18, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
April 04, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
March 16, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
March 14, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
March 02, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
February 16, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Participate in Three Upcoming Investor Conferences
February 06, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Resignation of Board Member
January 27, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
January 05, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
December 13, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present at Jefferies London Healthcare Conference
November 08, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
November 01, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022
October 31, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
October 26, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End
September 30, 2022
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.